ClinicalTrials.gg
CompletedNCT04704154Updated Apr 18, 2025Results posted

A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

A Phase 2 interventional study of Regorafenib, (Stivarga, BAY73-4506) and Nivolumab (Opdivo) in Solid Tumors, sponsored by Bayer. Completed at 34 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-18.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
175
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck — 11 open to participants now, 15 under way, 2 of them phase 3. Nivolumab · Squamous Cell Carcinoma of Head and Neck.

Enrollment
5th of 46
175 · median 44
Started
2021
with 1 other
Phase 2
27 of 46
10 open now
Registered
32nd of 46
by date
Lead sponsor
2 of 46
Bayer

Among the 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck, this one is the 5th largest by enrollment, is one of 2 that started in 2021, is one of 27 in phase 2, and was the 32nd registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

11 of the 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

Researchers are looking for a better way to treat people with solid tumors. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works.

In this trial, the researchers want to learn about regorafenib taken together with nivolumab in a small number of participants with different types of tumors. These include tumors in the head and neck, the esophagus, the pancreas, the brain, and the biliary tract. The biliary tract includes gall bladder and bile ducts.

The trial will include about 200 participants who are at least 18 years old. All of the participants will take 90 mg of regorafenib as a tablet by mouth. The dose of regorafenib can be adjusted up to 120 mg or down to 60 mg by the doctor based on how well a participant tolerates treatment. All of the participants will receive 480 milligrams (mg) of nivolumab through a needle put into a vein (IV infusion).

The participants will take treatments in 4-week periods called cycles. They will take regorafenib once a day for 3 weeks, then stop for 1 week. In each cycle, the participants will receive nivolumab one time. These 4-week cycles will be repeated throughout the trial. The participants can take nivolumab and regorafenib until their cancer gets worse, until they have medical problems, or until they leave the trial. The longest nivolumab can be given is up to 2 years.

During the trial, the doctors will take pictures of the participants' tumors using CT or MRI and will take blood and urine samples. The doctors will also do physical examinations and check the participants' heart health using an electrocardiogram (ECG). They will ask questions about how the participants are feeling and if they have any medical problems.

03

Conditions studied

  • Solid Tumors

Keywords

  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Esophageal Squamous Cell Carcinoma (ESCC)
  • Glioblastoma Multiforme (GBM)
  • Anaplastic Astrocytoma (AA)
  • Biliary Tract Carcinoma (BTC)
  • PD-1 inhibitor
  • nivolumab
  • regorafenib
  • multi-kinase inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed selected recurrent or solid tumor types that have progressed after treatment with standard therapies and for which there are no curative intent surgery or chemoradiation.
  • Cohort 1: subjects with HNSCC (Head and neck squamous-cell carcinoma) who have not received prior /PD-L1 inhibitor therapy.
  • Cohort 2: subjects with HNSCC who have progressed on or after prior systemic therapy, at least one of which included a PD-1/PD-L1 inhibitor alone or in combination with chemotherapy.
  • Cohort 3: subjects with ESCC (Esophageal Squamous Cell Carcinoma) who progressed on or after platinum and/or fluoropyrimidine based regimen.
  • Cohort 4: subjects with PDAC (Pancreatic ductal adenocarcinoma) who have progressed on or after gemcitabine or fluoropyrimidine based regimens.
  • Cohort 5: subjects with BTC (Biliary tract carcinoma) (intrahepatic or extrahepatic cholangiocarcinoma or gall bladder cancer) who have progressed on gemcitabine or fluoropyrimidine or platinum therapy or a combination of these agents.
  • Cohort 6: subjects with Grade IV GBM (Glioblastoma multiforme) or Grade III AA (Anaplastic astrocytoma) (World Health Organization [WHO] criteria) with unequivocal first progression after surgery followed by radiotherapy and temozolomide.
  • Documented HPV (Human papilloma virus) / p16 status for oropharyngeal cancer.
  • Capable of giving signed , including compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.
  • Adult participants of legal maturity (18 years or older).
  • (ECOG) Performance Status (PS) 0 to 1.
  • Adequate hematologic and organ function as assessed by the following laboratory tests performed within 7 d before start of study treatment including:

    • Total ≤1.5 x the (ULN). Total bilirubin (≤3 x ULN) is allowed if Gilbert's syndrome is documented
    • (ALT) and aspartate aminotransferase (AST) ≤3 x ULN (≤5 x ULN for participants with liver involvement of their cancer)
  • by baseline CT or MRI per 1.1 or RANO.
  • Participants must consent to provide recent /tumor tissue of a primary tumor lesion or from metastases (e.g. liver, lung) for HNSCC (IO treated) for Stage 1 and 2 and in HNSCC (IO naïve) cohort for Stage 2.
  • Anticipated greater than 3 months.
  • Be able to swallow and absorb oral tablets.

Exclusion criteria

Exclusion Criteria:

  • Presence of symptomatic central nervous system (CNS) , or spinal cord compression. Previously-treated lesions should be stable for at least 6 weeks prior to study entry.
  • Participants with a condition requiring systemic treatment with either (>10 mg daily prednisone equivalent) or other medications within 14 days of start of study treatment.
  • Prior therapy with /PD-L1 or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, or any form of immunotherapy to treat cancer (except cohort 2).
  • Cohort 2: More than one prior therapy with PD-1/PD-L1 or CTLA-4 inhibitors, or any other form of immunotherapy to treat cancer.
  • ESCC:

    • patients with apparent tumor invasion on organs located adjacent to the esophageal disease (e.g., the aorta or respiratory tract).
    • patients who have previously received taxane agents for recurrent/metastatic cancer.
  • GBM/AA

    • Primary tumors localized to the brainstem or spinal cord.
    • Presence of diffuse leptomeningeal disease or extracranial disease.
    • Participants requiring > 4 mg of dexamethasone or biologic equivalent per day to control symptoms related to brain tumor and cerebral edema within 21 days of starting study treatment.
  • Participants who have known dMMR/MSI-H cancers or NTRK (tropomyosin receptor kinase) fusions.
  • Prior therapy with regorafenib.
  • Systemic anti-cancer treatment within 14 days or less than 5 half-lives (whichever is shorter) of the first dose of study treatment.
  • Participants who have permanent discontinuation of PD-1/PD-L1 therapy due to toxicity.
  • Arterial thrombotic or embolic events such as cerebrovascular accident (including ) within 6 months before the start of study treatment. Active pulmonary emboli or deep vein thrombosis that are significant or not adequately controlled on anticoagulation regimen as per investigator's judgement.
  • History of cardiac disorders as defined by:

    • Congestive heart failure ≥ (NYHA) class 2:
    • Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months), myocardial infarction less than 6 months before start of study drug.
    • Uncontrolled cardiac arrhythmias.
  • Poorly controlled hypertension, defined as a blood pressure consistently above 140/90 mmHg despite optimal medical management.
  • Participants with an active, known or suspected disease.
  • History of (non-infectious) pneumonitis that required steroids, current pneumonitis or interstitial lung disease.
  • Active infection > Grade 2.
  • Positive test (from historical data or tested during screening) for (HIV) or known acquired immunodeficiency syndrome (AIDS).
  • Any positive test result for virus (HBV) or virus (HCV) indicating presence of virus, e.g. Hepatitis B surface antigen (HBsAg, Australia antigen) positive (except for participants on anti-viral therapy for HBV with a viral load \< 100 IU/mL), or Hepatitis C antibody (anti-HCV) positive (except if HCV-ribonucleic acid [RNA] negative).
  • Pregnancy or breast feeding.
  • Known to any of the study drugs, study drug classes, or in the formulation.
  • History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial or interfere with the participation for the full duration of the trial.
  • Participants with a current or past history of interstitial lung disease or pulmonary fibrosis diagnosed based on imaging or clinical findings.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    Regorafenib+Nivolumab

    Parallel-cohort in adult participants with selected recurrent or metastatic tumors (HNSCC, ESCC, PDAC, BTC, and GBM/AA) who have been previously treated with one or more systemic therapy for the selected tumor indication.

    Drug: Regorafenib, (Stivarga, BAY73-4506) · Drug: Nivolumab (Opdivo)

Interventions

  • Intake orally, starting with 3x 30 mg tablets every day (once daily.) for 21 days of every 28-day cycle (21 days on, 7 days off). If the starting dose is well tolerated dose can be escalated to 120 mg (4x30 mg tablets).

  • 480 mg administered on Day 1 of each treatment cycle.

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    Tumor response was evaluated as ORR per RECIST 1.1 by local assessments for all tumor types, except for GBM/AA, where ORR per RANO by local assessment was used. ORR was defined as the proportion of participants with best overall response of complete response (CR) or partial response (PR). Participants for whom best overall tumor response was not CR or PR, as well as participants without any post-baseline tumor assessment were considered non-responders. Descriptive statistics were done, no inferential statistical analyses were performed.

    Time frame: From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 months

Secondary outcomes

  1. Duration of Response (DOR)

    Defined as the time (in days) from the first documented objective response of PR or CR, whichever is noted earlier, to disease progression or death (if death occurs before progression is documented). DOR will be defined for responders only, i.e. participants with a CR or PR.

    Time frame: From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 months

  2. Disease Control Rate (DCR)

    CR = Complete response; PR = Partial response; SD = Stable disease

    Time frame: From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 months

  3. Progression Free Survival (PFS)

    PFS was defined as the time (in days) from the start of study intervention to the date of first objectively documented progressive disease (PD) or death from any cause (if no progression was documented).

    Time frame: From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 months

  4. 6 Months PFS

    6 Months PFS rate

    Time frame: Up to last participant follow 6 months (approximately 22 months)

  5. Overall Survival (OS)

    OS was defined as the time (in days) from the start of study intervention to the date of death due to any cause.

    Time frame: From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 months

  6. 1 Year OS

    Time frame: From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 month]

  7. Number of Participants With Adverse Events

    AEs were considered to be treatment-emergent (TEAEs) if they started or worsened after the start of first study drug administration until 30 days after regorafenib treatment discontinuation or 100 days after the last dose of nivolumab, whatever occurred later.

    Time frame: Up to the last participant has been followed for approximately 10 months, summed up to approximately 26 months

07

Results

Posted Jul 23, 2024

Participant flow

The study was conducted at 34 study centers in 8 countries/regions from 03 February 2021 (first patient first visit) to 29 March 2024 (last patient last visit)

Participant flow — Overall Study
MilestoneHNSCC (IO Naive)HNSCC (IO Treated)ESCCPDACBiliary Tract Cancer (BTC)GBM/AA
Started302030204530
Completed000000
Not completed302030204530
Withdrew: Adverse event324230
Withdrew: Death300030
Withdrew: Physician decision101020
Withdrew: Participant decision110000
Withdrew: Progressive disease191720183630
Withdrew: Completed max. allowed treatment. a max. of 24 infusions of nivolumab were allowed for participants201010
Withdrew: Patient continued in rollover study for regorafenib104000

Outcome measures

PrimaryOverall Response Rate (ORR)

Tumor response was evaluated as ORR per RECIST 1.1 by local assessments for all tumor types, except for GBM/AA, where ORR per RANO by local assessment was used. ORR was defined as the proportion of participants with best overall response of complete response (CR) or partial response (PR). Participants for whom best overall tumor response was not CR or PR, as well as participants without any post-baseline tumor assessment were considered non-responders. Descriptive statistics were done, no inferential statistical analyses were performed.

Time frame:
From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 months
Reported as:
Count of participants · Participants
Overall Response Rate (ORR)
ParticipantsHNSCC (IO Naive)HNSCC (IO Treated)ESCCPDACBiliary Tract Cancer (BTC)GBM/AA
Overall Response Rate (ORR)6115021
SecondaryDuration of Response (DOR)

Defined as the time (in days) from the first documented objective response of PR or CR, whichever is noted earlier, to disease progression or death (if death occurs before progression is documented). DOR will be defined for responders only, i.e. participants with a CR or PR.

Time frame:
From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 months
Reported as:
Median · Days
Duration of Response (DOR)
DaysHNSCC (IO Naive)HNSCC (IO Treated)ESCCPDACBiliary Tract Cancer (BTC)GBM/AA
Duration of Response (DOR)NA (654 to NA)NA (NA to NA)420 (112 to 617)—432 (112 to NA)140 (NA to NA)
SecondaryDisease Control Rate (DCR)

CR = Complete response; PR = Partial response; SD = Stable disease

Time frame:
From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 months
Reported as:
Count of participants · Participants
Disease Control Rate (DCR)
ParticipantsHNSCC (IO Naive)HNSCC (IO Treated)ESCCPDACBiliary Tract Cancer (BTC)GBM/AA
Disease Control Rate (DCR)16132272410
SecondaryProgression Free Survival (PFS)

PFS was defined as the time (in days) from the start of study intervention to the date of first objectively documented progressive disease (PD) or death from any cause (if no progression was documented).

Time frame:
From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 months
Reported as:
Median · Days
Progression Free Survival (PFS)
DaysHNSCC (IO Naive)HNSCC (IO Treated)ESCCPDACBiliary Tract Cancer (BTC)GBM/AA
Progression Free Survival (PFS)79 (50 to 227)105 (52 to 115)259 (110 to 472)53 (48 to 111)98 (55 to 112)55 (52 to 84)
Secondary6 Months PFS

6 Months PFS rate

Time frame:
Up to last participant follow 6 months (approximately 22 months)
Reported as:
Number · Proportion of participants
6 Months PFS
Proportion of participantsHNSCC (IO Naive)HNSCC (IO Treated)ESCCPDACBiliary Tract Cancer (BTC)GBM/AA
6 Months PFS0.455 (0.337 to 0.573)0.263 (0.134 to 0.393)0.533 (0.417 to 0.650)0.050 (0.000 to 0.112)0.148 (0.077 to 0.218)0.167 (0.079 to 0.254)
SecondaryOverall Survival (OS)

OS was defined as the time (in days) from the start of study intervention to the date of death due to any cause.

Time frame:
From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 months
Reported as:
Median · Days
Overall Survival (OS)
DaysHNSCC (IO Naive)HNSCC (IO Treated)ESCCPDACBiliary Tract Cancer (BTC)GBM/AA
Overall Survival (OS)358 (198 to 418)355 (126 to 614)627 (431 to 865)259 (134 to 311)246 (176 to 386)245 (127 to 377)
Secondary1 Year OS
Time frame:
From first participant enrolled to cut-off date (ie after the last participant has been followed for approximately 10 months) approximately 26 month]
Reported as:
Number · Proportion of participants
1 Year OS
Proportion of participantsHNSCC (IO Naive)HNSCC (IO Treated)ESCCPDACBiliary Tract Cancer (BTC)GBM/AA
1 Year OS0.415 (0.298 to 0.532)0.444 (0.294 to 0.595)0.764 (0.664 to 0.864)0.281 (0.145 to 0.418)0.422 (0.323 to 0.521)0.337 (0.223 to 0.451)
SecondaryNumber of Participants With Adverse Events

AEs were considered to be treatment-emergent (TEAEs) if they started or worsened after the start of first study drug administration until 30 days after regorafenib treatment discontinuation or 100 days after the last dose of nivolumab, whatever occurred later.

Time frame:
Up to the last participant has been followed for approximately 10 months, summed up to approximately 26 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsHNSCC (IO Naive)HNSCC (IO Treated)ESCCPDACBiliary Tract Cancer (BTC)GBM/AA
Any AE302030204530
Worst grade: Grade 1102010
Worst grade: Grade 2416298
Worst grade: Grade 3161618112311
Worst grade: Grade 4622212
Worst grade: Grade 5 (death)3125119

Adverse events

Collected over Up to the last participant has been followed for approximately 10 months, summed up to approximately 26 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HNSCC (IO Naive)22/30 (73.3%)22/30 (73.3%)30/30 (100%)
HNSCC (IO Treated)17/20 (85%)15/20 (75%)20/20 (100%)
ESCC20/30 (66.7%)19/30 (63.3%)30/30 (100%)
PDAC17/20 (85%)13/20 (65%)20/20 (100%)
Biliary Tract Cancer (BTC)36/45 (80%)28/45 (62.2%)45/45 (100%)
GBM/AA27/30 (90%)13/30 (43.3%)29/30 (96.7%)
Most frequent serious events
Showing 10 of 97
Most frequent serious events
EventHNSCC (IO Naive)HNSCC (IO Treated)ESCCPDACBiliary Tract Cancer (BTC)GBM/AA
General physical health deteriorationGeneral disorders2/301/200/301/207/459/30
PneumoniaInfections and infestations4/304/204/300/201/450/30
CholangitisHepatobiliary disorders0/300/200/300/205/450/30
Bile duct stenosisHepatobiliary disorders0/300/200/302/200/450/30
DysphagiaGastrointestinal disorders2/301/201/300/200/450/30
PancreatitisGastrointestinal disorders1/300/202/300/200/450/30
Septic shockInfections and infestations0/300/202/300/200/450/30
HypercalcaemiaMetabolism and nutrition disorders2/300/200/300/200/450/30
Decreased appetiteMetabolism and nutrition disorders2/301/201/300/200/450/30
PneumonitisRespiratory, thoracic and mediastinal disorders0/301/202/300/200/450/30
Most frequent other events
Showing 10 of 204
Most frequent other events
EventHNSCC (IO Naive)HNSCC (IO Treated)ESCCPDACBiliary Tract Cancer (BTC)GBM/AA
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders8/309/2022/305/2015/458/30
RashSkin and subcutaneous tissue disorders6/302/2014/308/2010/455/30
Decreased appetiteMetabolism and nutrition disorders8/309/2011/307/2014/456/30
FatigueGeneral disorders4/307/209/308/2019/455/30
ConstipationGastrointestinal disorders7/308/207/307/2015/4511/30
PyrexiaGeneral disorders6/306/2012/307/2017/455/30
DiarrhoeaGastrointestinal disorders7/303/2011/303/2017/456/30
Abdominal painGastrointestinal disorders0/301/204/307/2011/454/30
NauseaGastrointestinal disorders3/302/205/307/2014/454/30
HypertensionVascular disorders5/307/204/306/2011/458/30

Baseline characteristics

Full analysis set (FAS): all participants who received study treatment were included in the full analysis set

Age, Customized
Age, Customized(Participants)HNSCC (IO Naive)HNSCC (IO Treated)ESCCPDACBiliary Tract Cancer (BTC)GBM/AATotal
<65 years16101713172295
65-<75 years12411722763
75-<85 years26206117
Sex: Female, Male
Sex: Female, Male(Participants)HNSCC (IO Naive)HNSCC (IO Treated)ESCCPDACBiliary Tract Cancer (BTC)GBM/AATotal
Female56311201055
Male25142792520120
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HNSCC (IO Naive)HNSCC (IO Treated)ESCCPDACBiliary Tract Cancer (BTC)GBM/AATotal
American Indian or Alaska Native0000000
Asian151121511265
Native Hawaiian or Other Pacific Islander0000000
Black or African American0000101
White66713272685
More than one race0000000
Unknown or Not Reported93226224
08

Study locations

34 sites
  • City of Hope - Duarte Cancer Center
    Duarte, California 91010, United States
  • Rocky Mountain Cancer Centers / Aurora, CO
    Aurora, Colorado 80012, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Sarah Cannon Cancer Center
    Nashville, Tennessee 37203, United States
  • Baylor Charles A. Sammons Cancer Center at Dallas
    Dallas, Texas 75246, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Hôpital Erasme/Erasmus Ziekenhuis
    Brussels, 1070, Belgium
  • UZ Antwerpen
    Edegem, 2650, Belgium
  • CHU de Liège
    Liege, 4000, Belgium
  • Institut Bergonie - Unicancer Nouvelle Aquitaine
    Bordeaux Cedex, 33076, France
  • UNICANCER - Centre Leon Berard (CLB)
    Lyon, 69008, France
  • APHP-Hopital la Pitie Salpetriere
    Paris, 75651, France
  • Institut de Cancerologie Ouest - Saint-Herblain
    Saint-Herblain, 44800, France
  • Institut Claudius Regaud - iUCT Oncopole
    Toulouse Cedex 9, 31059, France
  • Gustave Roussy - Departement Oncologie-Radiotherapie
    Villejuif Cedex, 94805, France
  • AUSL di Bologna_Istituto delle Scienze Neurologiche - UO Oncologia del Sistema Nervoso
    Bologna, Emilia-Romagna 40139, Italy
  • IRCCS Foundation Istituto Neurologico Carlo Besta
    Milano, Lombardia 20133, Italy
  • Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia
    Rozzano, Lombardia 20089, Italy
  • Istituto Oncologico Veneto_Padova - UOC Oncologia 1
    Padova, Veneto 35128, Italy
  • ASST Grande Ospedale Metropolitano Niguarda - Oncologia Falck
    Milan, 20162, Italy
  • Aichi Cancer Center Hospital
    Nagoya, Aichi 464-8681, Japan
  • Kobe University Hospital
    Kobe, Hyogo 650-0017, Japan
  • Saitama Cancer Center
    Kitaadachi-gun, Saitama 362-0806, Japan
  • National Cancer Center Hospital
    Chuo-ku, Tokyo 104-0045, Japan
  • The Cancer Institute Hospital of JFCR
    Koto-ku, Tokyo 135-8550, Japan
  • Severance Hospital, Yonsei University Health System
    Seoul, Seoul Teugbyeolsi 03722, Korea, Republic of
  • Seoul National University Hospital
    Seoul, Seoul Teugbyeolsi 3080, Korea, Republic of
  • Chi Mei Medical Center
    Taikang, Tainan 71004, Taiwan
  • China Medical University Hospital
    Taichung, 404327, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
  • Royal Marsden NHS Trust (Surrey)
    Sutton, Surrey SM2 5PT, United Kingdom
  • University Hospitals Coventry and Warwickshire NHS Trust
    Coventry, West Midlands CV2 2DX, United Kingdom
  • Beatson West of Scotland Cancer Centre
    Glasgow, G12 0YN, United Kingdom
  • The Royal Marsden NHS Foundation Trust | The Royal Marden Hospital - The Royal Marsden Clinical Trials Unit (CTU)
    London, SW3 6JJ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Mar 2023, 25 months.

Results were first posted in Jul 2024, 1 year 4 months after primary completion.

Of 68 industry-sponsored phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 25 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2021
First posted
Jan 11, 2021
StartActual
Feb 3, 2021
Primary completionActual
Mar 9, 2023
CompletionActual
Mar 29, 2024
Results first posted
Jul 23, 2024
Last update
Apr 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04704154
Lead sponsor
Bayer
Collaborators
Bristol Myers Squibb Co. and Ono Pharmaceutical Co., Ltd
Responsible party
Sponsor
First posted
Jan 11, 2021
Start date
Feb 3, 2021
Primary completion
Mar 9, 2023
Completion
Mar 29, 2024
Results posted
Jul 23, 2024
Last update
Apr 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Regorafenib · Nivolumab

Start the discussion